Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kataja, V. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kataja, V. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1010-1011, 2003
© 2003 European Society for Medical Oncology

Original Paper

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer

V. V. Kataja

Department of Oncology, University Hospital of Kuopio, Kuopio, Finland

The first 10% of the full text of this article appears below.


   Incidence
 

The age-standardized incidence of prostate cancer in the European Union is 65/100 000, and mortality 26/100 000 per year. It is the most common male cancer in Western Europe and the Nordic countries. The mean diagnostic age is 71 years. Latent sub-clinical prostate cancer is very common in men >80 years. Only 1 in 10 latent cancers will eventually become clinical cancers.


   Early diagnosis
 

Early diagnosis (screening) . . . [Full Text of this Article]


   Staging
 

   Treatment of localized prostate cancer (T1–4NXM0)
 

   Treatment of metastatic prostate cancer
 

   Follow-up
 

   Note
 

   Literature
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?